Search results
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide.
Our company. We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
At AstraZeneca we’re united by our desire to push the boundaries of science to deliver life-changing medicines. We know it’s how we will continue to transform the lives of millions of patients around the world while delivering value to our employees, our communities, and the environment.
To tackle some of the world’s greatest healthcare challenges, we’ve created an inspiring working environment with world-class talent and opportunities. In India, we merge our brightest minds and cutting-edge resources to make a real difference to lives the world over. Search jobs.
AstraZeneca | 2,923,451 followers on LinkedIn. What science can do | We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the...
Feb 28, 2023 · PUBLISHED 28 February 2023. AstraZeneca completed the acquisition of Alexion in the year 2021 and is now expanding its portfolio globally to bring innovative therapies for patients living with rare diseases in India. Receives regulatory approval for its molecule ‘Selumetinib’ in India.
Feb 3, 2021 · COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials. 3 February 2021 07:00 GMT. The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca ...
The AstraZeneca vaccine has an efficacy of 72% against symptomatic SARS-CoV-2 infection, as shown by the primary analysis of data irrespective of interdose interval from trial participants who received 2 standard doses with an interval varying from about 4 to 12 weeks.
Apr 23, 2021 · Vaxzevria (formerly COVID-19 Vaccine AstraZeneca) is authorised in the EU to prevent COVID-19, which can cause severe disease and death. The disease can also have long-term consequences in people of all ages, including in otherwise healthy people.
